Aoxing Pharmaceutical Company to Host Investor Luncheons in Dallas, San Francisco and San Diego
JERSEY CITY, NJ / ACCESSWIRE / October 16, 2015 / Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN), a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, will be hosting investor luncheons from noon to 1:30 p.m. in Dallas, TX on October 21st, 2015, San Francisco, CA on October 22nd, 2015, and San Diego, CA on October 23rd.
The luncheons will provide investors an opportunity to hear from and meet members of the Aoxing Pharma management team. Management will discuss the Company’s continued growth, success within the pharmaceutical industry and recent earnings announcement. Each luncheon will feature a presentation about Aoxing Pharma’s line of products and how management plans to better position Aoxing for immediate and long-term growth and enhanced profitability.
To RSVP for one of the luncheons please contact :
Asia IR – PR
Jimmy Caplan, 512-329-9505
jimmy@asia-irpr.com
Please indicate the names of those who will be attending from your firm and indicate which location (Dallas, San Francisco, San Diego) you prefer, so we can accommodate you. After we receive your RSVP, you will receive a confirmation for your attendance.
DALLAS
Executive Presentation and Question & Answer Session: Noon to 1:30 p.m.
Location: The Adolphus Hotel
1321 Commerce Street Dallas, TX 75202
Room: Sam Rayburn A
Tel:(214) 742-8200
www.hoteladolphus.com
SAN FRANCISCO
Executive Presentation and Question & Answer Session: Noon to 1:30 p.m.
Location:The Palace Hotel
2 New Montgomery Street San Francisco, CA 94105
Tel: (415) 512-1111
Hotel Information: www.sfpalace.com
SAN DIEGO
Executive Presentation and Question & Answer Session: Noon to 1:30 p.m.
Location: The Westgate Hotel
Address: 1022 Second Avenue, San Diego, CA 92101
Tel: (619) 238-1818
Hotel Information: www.westgatehotel.com
Aoxing Pharmaceutical Company:
646-367-1747
investor.relations@aoxingpharma.com
SOURCE: Aoxing Pharmaceutical Company, Inc.
ReleaseID: 432757